vTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq

After a rocky few years of leadership changes and net losses, including $5.6 million in Q2, High Point's vTv Therapeutics is in danger of being delisted from Nasdaq.